KBD880
/ Chengdu Baiyu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
KBD880 is a potent and selective GPC3 peptide binder for treatment of HCC
(AACR 2026)
- "KBD880 is a potent and selective, peptide-based radiopharmaceutical agent developed for targeting GPC3-expressing tumors. Its favorable preclinical characteristics—including an optimal pharmacokinetic profile, targeted biodistribution, and durable monotherapy efficacy—strongly support its development as a theranostic agent for patients with GPC3-positive malignancies."
Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
1 to 1
Of
1
Go to page
1